X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Holly Campbell

Holly Campbell Holly Campbell is a deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.

Recent Posts

New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis

By Holly Campbell  |    February 14, 2019
New research by three Milliman actuaries explores the dynamics underlying the relationship between Medicare Part D plan premiums and sharing rebates directly with beneficiaries at the pharmacy...   Read More

New IQVIA data show medicine prices grew just 1.5 percent in 2018

By Holly Campbell  |    January 29, 2019
Last year, the U.S. Food and Drug Administration approved a record of 59 novel new medicines. During this incredible era of innovation, medicine prices grew just 1.5 percent in 2018, after...   Read More

Health Affairs study misses the mark on medicine costs

By Holly Campbell  |    January 28, 2019
A recent study published in Health Affairs concludes that list price inflation for existing brand medicines is a key driver of rising medicine spending. However, by failing to account for the...   Read More

New government data show medicine price growth continues to decline

By Holly Campbell  |    January 18, 2019
Last year, the U.S. Food and Drug Administration approved a record 59 new treatments and cures. During this incredible period of innovation, medicine price growth continued to slow dramatically.   Read More

New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions

By Holly Campbell  |    January 18, 2019
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) potential budget impact analyses are not...   Read More

10 things you should know about medicine spending and costs

By Holly Campbell  |    January 2, 2019
Discussions about costs are important. Too often patients struggle to afford the medicines they need. Our industry is committed to working with policymakers on solutions that enhance the...   Read More

Six key facts about the market for insulins

By Holly Campbell  |    December 17, 2018
The insulin market is commonly mischaracterized as lacking competition. In fact, robust competition among biopharmaceutical companies that produce insulin results in increasing levels of discounts...   Read More

PhRMA CEO discusses industry’s new approach to DTC television advertising

By Holly Campbell  |    October 17, 2018
PhRMA president and CEO Stephen J. Ubl joined CBS This Morning and MSNBC Live with Ali Velshi to discuss PhRMA member companies’ commitment to providing patients with the information they need to...   Read More

What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising

By Holly Campbell  |    October 15, 2018
Pharmaceutical Research and Manufacturers of America (PhRMA) member companies today announced their commitment to providing more transparency about medicine costs to help patients make more...   Read More

New study finds some hospitals mark up medicine prices at least 700 percent

By Holly Campbell  |    September 5, 2018
A new analysis from The Moran Company found nearly one in five hospitals marks up medicine prices 700 percent or more. With this 700 percent markup, a $150 medicine purchased by a hospital could...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates